Novartis marketing services center lands in Ireland; Pfizer faces delay in tearing down Groton building;

 @FiercePharma: CDC study finds U.S. adults still skipping their meds to save money. Until they qualify for Medicare. Report | Follow @FiercePharma

 @EricPFierce: Fleming Laboratories has two plants in Pradesh, India, which were put on import alert Monday by the FDA. Alert | Follow @EricPFierce

> Novartis ($NVS) picked Dublin, Ireland, for a business services center that will employ 100 people; the operation will handle digital marketing, salesforce training and medical communications in Europe. Report

> Pfizer ($PFE) faces a roadblock in its plans for demolishing a former R&D facility in Groton, CT; the city approved an emergency ordinance establishing a 90-day waiting period. Report

> India's trade minister defended the Supreme Court's decision to deny patent protection to Novartis' cancer drug Gleevec, saying the ruling was "justified under the law." Report

> India pushed back its deadline for adding barcodes to pharma exports, giving the industry an extra year to comply with a new track-and-trace system. Report

> Growth in drug ingredients helped fuel an increase in sales at Arseus to $173 million. Report

Medical Device News

 @FierceMedDev: Blood test reveals more vivid GI cancer gene mutations. More | Follow @FierceMedDev

 @MarkHFierce: The U.K. govt is supporting development of an anti-obesity electronic implant, at Imperial College London. Report | Follow @MarkHFierce

 @DamianFierce: The AP has an excellent roundup of all that's happened with $ISRG over the past month or so. More | Follow @DamianFierce

> Former Abaxis worker settles SEC insider trading case. More

> Biomet's sales soar, losses widen after DePuy buyout. Story

> Bausch + Lomb wins FDA panel nod for eye implant. News

Biotech News

 @FierceBiotech: FDA approved morning-sickness pill, to be marketed as Diclegis. Release | Follow @FierceBiotech

 @JohnCFierce: Bristol-Myers' new R&D chief lays out PhIII game plan. More | Follow @JohnCFierce.

 @RyanMFierce: Elsevier scoops up startup Mendeley in controversial bet on open science. Is it worth it? News | Follow @RyanMFierce

> Lundbeck touts promising head-to-head data on depression drug Brintellix. More

> NEA provides $10M to help fuel next-gen cancer R&D at Cleave. Report

> Gilead quickly asks FDA for blockbuster hep C approval. Story

Pharma Manufacturing News

> China, India have yet to meet EU rule on APIs. More

> More Doxil made through J&J 'alternative manufacturing.' Report

> China drugmaker pulls flu treatment tainted with toxic herbs. Story

> Apotex recalls birth control pills. Article

Biotech Research News

 @EmilyMFierce: Merck developing new class of drugs to target therapy-resistant cancer driven by genetic mutations. Report | Follow @EmilyMFierce

> Common sweetener mannitol improves motor functions in Parkinson's flies. More

> Targeted brain stimulation could treat addiction. Item

> New cancer radiation treatment has no harmful side effects in mice. Article

> Some still skeptical of BRAIN initiative as details remain fuzzy. Story

And Finally... China reported a seventh death from a new form of avian flu and two more cases of infection. Report (sub. req.)

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.